
Anti-Human PD-L1 (Atezolizumab) - PE





IVMB0465

Product Information

Product SKU: IVMB0465 Clone: RG7446 Target: PD-L1

Size: 50 µg Isotype: Human IgG

Additional Information

Reactivity: Human **Host Species**: Human

Antibody Type: Biosimilar Recombinant Human Monoclonal Antibody **Expression Host**: HEK-293 Cells

Immunogen Information

Background: PD-1 is a 50-55 kD member of the B7 Iq superfamily. PD-1 is also a member of the extended

> CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also

> members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune

responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been

reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with

its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation

and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of

the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by

improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the

field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-

CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions.

Regulation of T cell responses, including enhanced T cell proliferation and cytokine

production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Product Concentration: 0.2 mg/ml

Applications: FC

Synonyms: Programmed Death Ligand 1, B7-H1, PD-L1, CD274



Antigen Distribution: PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-y activated endothelial cells,

and monocytes.

Immunogen: Unknown

Formulation: This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline

(150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Specificity: This non-therapeutic biosimilar antibody uses the same variable region sequence as the

therapeutic antibody Atezolizumab. Atezolizumab recognizes an epitope on mouse PD-L1.

This product is for research use only.

Pathogen Testing: To protect mouse colonies from infection by pathogens and to assure that experimental

preclinical data is not affected by such pathogens, all of Leinco's recombinant biosimilar

antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT

I Mouse Profile.

Storage & Handling: Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to

one month. For longer term storage, aseptically aliquot in working volumes without diluting

and store at -80°C. Avoid Repeated Freeze Thaw Cycles.